These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 6610022)

  • 1. Phase II trial of thymosin fraction 5 in advanced renal cancer.
    Schulof RS; Lloyd MJ; Ueno WM; Green LD; Stallings JJ
    J Biol Response Mod; 1984; 3(2):151-9. PubMed ID: 6610022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects.
    Schulof RS; Simon GL; Sztein MB; Parenti DM; DiGioia RA; Courtless JW; Orenstein JM; Kessler CM; Kind PD; Schlesselman S
    J Biol Response Mod; 1986 Oct; 5(5):429-43. PubMed ID: 3490545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma.
    Dimitrov NV; Arnold D; Munson J; Singh T; Borst J; Stott P
    Cancer Treat Rep; 1985 Jan; 69(1):137-8. PubMed ID: 3967256
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of thymosin fraction 5 and thymosin alpha 1.
    Dillman RO; Beauregard J; Royston I; Zavanelli MI
    J Biol Response Mod; 1987 Jun; 6(3):263-7. PubMed ID: 3598602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
    Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
    Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin alpha 1.
    Dillman RO; Beauregard JC; Zavanelli MI; Halliburton BL; Wormsley S; Royston I
    J Biol Response Mod; 1983; 2(2):139-49. PubMed ID: 6315897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD; Raefsky EL; Greco FA
    Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
    J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
    Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
    Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma.
    Todd RF; Garnick MB; Canellos GP; Richie JP; Gittes RF; Mayer RJ; Skarin AT
    Cancer Treat Rep; 1981; 65(1-2):17-20. PubMed ID: 7226167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
    Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
    Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.